Body Protection
Compound.
The most-studied peptide in the Pepra catalog. A synthetic 15-amino-acid fragment derived from a protein in human gastric juice — studied across three decades of preclinical work for tissue, tendon, and mucosal repair.
From$40 / month · 4-week starter cycleWhat BPC-157 is, exactly.
BPC-157 — short for Body Protection Compound 157 — is a synthetic fragment of a protein originally identified in human gastric juice. The fragment is fifteen amino acids long, with a sequence that has been remarkably stable across the studies that defined it: Gly-Glu-Pro-Pro-Pro- Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
It is most commonly studied for its ability to support repair of soft tissue — tendons, ligaments, mucosal lining of the stomach and intestine, and the vascular structures supplying them. The proposed mechanism centers on local angiogenesis (new blood vessel formation in the area of injury) and modulation of nitric oxide and growth factor pathways.
What the human evidence shows.
We are honest about evidence quality. Animal data is robust: several hundred preclinical studies across three decades, with consistent findings for tendon and ligament repair, GI mucosal protection, and reduction of NSAID-induced gastric injury.
Human trial data remains limited but is no longer absent. Phase I and early Phase II work is underway in several centers; case-series data on chronic tendinopathy and Crohn's-related GI symptoms is accumulating. For now, your prescriber will weigh that evidence against your individual presentation rather than treating BPC-157 as a finished, FDA-approved drug.
We update this page as new data is published. The clinical primer you receive with your prescription includes a citations packet.
Who BPC-157 may be for.
- Adults with chronic or post-acute musculoskeletal injuries that haven't fully resolved with rest, PT, or NSAIDs.
- Patients with persistent gastric or intestinal lining issues — particularly NSAID-related gastritis or post-IBD flare recovery.
- Athletes and active adults dealing with tendinopathy, plantar fasciitis, or chronic shoulder/knee dysfunction.
- Patients planning post-surgical recovery, in coordination with their primary care or surgical team.
Side-effect profile.
Generally well tolerated in available data. The most commonly reported effects across literature and our own intake notes:
- Mild injection-site reaction — redness, warmth, or transient itching at the subcutaneous site, usually fading within 24 hours.
- Transient nausea or fatigue in the first week, particularly when dosed without food.
- Vivid dreams reported by a minority of patients during the first 7–10 days.
BPC-157 is not for use during pregnancy, while breastfeeding, or with active malignancy. Patients on antiplatelet or anticoagulant therapy require additional clinician review.
How a typical Pepra protocol runs.
Most BPC-157 protocols at Pepra run as a 4-week starter cycle at 250 mcg once daily, subcutaneous, with a 4-week follow-up message from your prescriber. Patients with chronic injuries or extensive prior care often extend to 8 weeks. After the cycle ends, most patients pause; some re-cycle 2–3 months later.
The vials ship cold-shipped, refrigerated. Each 5 mg vial reconstitutes to roughly a 4–5 week supply at the standard dose. We include the bacteriostatic water, syringes, alcohol pads, sharps return mailer, and a one-page primer for your first dose.
BPC-157 is a compounded medication, not an FDA-approved finished drug. The active ingredient is permitted under 503A compounding under a valid individual prescription. Compounded medications carry their own oversight framework — which is what Pepra's prescriber network and 503A pharmacy partners exist to provide.
Selected references
- 1.Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157" — Curr Pharm Des. 2010;16(10):1224-34.
- 2.Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing" — J Appl Physiol. 2011;110:774-80.
- 3.Cerovecki T, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing" — J Orthop Res. 2010;28(9):1155-61.
- 4.Sikiric P, et al. "BPC 157 and standard angiogenic growth factors" — Curr Pharm Des. 2018;24(18):1972-1989.
- 5.Vukojević J, et al. "Rat brain ischemia/reperfusion and BPC 157" — Curr Neuropharmacol. 2020;18(8):800-810.
- 6.Park JM, et al. "Pentadecapeptide BPC 157 in NSAID-induced gastric mucosal injury" — Inflammopharmacology. 2020;28:147-155.